Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :26747862
Publication Date : //

Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.


The proliferation and activation of microglial cells is a hallmark of several neurodegenerative conditions. This mechanism is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus providing a target that may prevent the progression of conditions such as Alzheimer's disease. However, the study of microglial proliferation in Alzheimer's disease and validation of the efficacy of CSF1R-inhibiting strategies have not yet been reported. In this study we found increased proliferation of microglial cells in human Alzheimer's disease, in line with an increased upregulation of the CSF1R-dependent pro-mitogenic cascade, correlating with disease severity. Using a transgenic model of Alzheimer's-like pathology (APPswe, PSEN1dE9; APP/PS1 mice) we define a CSF1R-dependent progressive increase in microglial proliferation, in the proximity of amyloid-β plaques. Prolonged inhibition of CSF1R in APP/PS1 mice by an orally available tyrosine kinase inhibitor (GW2580) resulted in the blockade of microglial proliferation and the shifting of the microglial inflammatory profile to an anti-inflammatory phenotype. Pharmacological targeting of CSF1R in APP/PS1 mice resulted in an improved performance in memory and behavioural tasks and a prevention of synaptic degeneration, although these changes were not correlated with a change in the number of amyloid-β plaques. Our results provide the first proof of the efficacy of CSF1R inhibition in models of Alzheimer's disease, and validate the application of a therapeutic strategy aimed at modifying CSF1R activation as a promising approach to tackle microglial activation and the progression of Alzheimer's disease.

Authors : Olmos-Alonso Adrian , Schetters Sjoerd T T , Sri Sarmi , Askew Katharine , Mancuso Renzo , Vargas-Caballero Mariana , Holscher Christian , Perry V Hugh , Gomez-Nicola Diego ,

Related products :

Catalog number Product name Quantity
26-850 IL9 is a cytokine that acts as a regulator of a variety of hematopoietic cells. This cytokine stimulates cell proliferation and prevents apoptosis. It functions through the interleukin 9 receptor (IL9 0.05 mg
orb61370 Sorafenib Tosylate Sorafenib (Bay 43-9006) is a novel bi-aryl urea compound that inhibits the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR- beta and their 500 mg
orb60237 Bendamustine Hydrochloride Bendamustine inhibits SU-DHL-1 cell proliferation with IC50 at 50 50 mg
31-125 APBA1 is a member of the X11 protein family. It is a neuronal adaptor protein that interacts with the Alzheimer's disease amyloid precursor protein (APP). It stabilises APP and inhibits production of 0.05 mg
1331 Ovary disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replacing OV1005
1426 Pancreas disease spectrum (pancreatic cancer progression) tissue array, including TNM, clinical stage and pathology grade, 103 cases_208 cores, replacing PA2081
BC07001 Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores
BC07001 Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores
BC06002 Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores
BC06002 Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores
PA2081 Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases_208 cores
CO2081 Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases_208 cores
CO2081 Colon disease spectrum (colon cancer progression) tissue array, including TNM and pathology grade, 103 cases_208 cores; ihc Anti-Actin confirmed
BC06002 Rectum disease spectrum (rectum cancer progression) tissue array, including TNM and pathology grade, 63 cases_72 cores; ihc Anti-Actin confirmed
PA2081 Pancreatic disease spectrum (pancreatic cancer progression) tissue array with pathology grade and TNM information, 101 cases_208 cores; ihc Anti-Actin confirmed
BC07001 Kidney disease spectrum (kidney cancer progression) tissue array, including TNM and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed
OV1005a Ovary disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replacing OV1005; ihc Anti-Actin confirmed
OV1005 Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replacing OV1001
26-231 LAPTM4B is a multi-pass membrane protein. It belongs to the LAPTM4_LAPTM5 transporter family. LAPTM4b has active role in disease progression of malignant cells and is involved in cell proliferation an 0.05 mg
OV1005 Ovarian disease spectrum (ovarian cancer progression) tissue array, including TNM, clinical stage and pathology grade, 100 cases_100 cores, replaced by OV1005a; ihc Anti-Actin confirmed
orb82687 Human EMAP 2 protein EMAP 2 is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculo 1 mg
A3019 CSF1R Primary Antibody, CSF1R, Species: Human Synthetic peptide Source: Rabbit Polyclonal 50ug
orb61328 Enzastaurin Enzastaurin inhibits PKCbeta, PKCalpha, PKCγ and PKCε with IC50s of 0.006, 0.039, 0.083 and 0.110 µM, respectively. Enzastaurin apparently inhibits tumor growth via multiple mechanisms. Fo 25 mg
31-050 MDM4 inhibits p53- and p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. It inhibits degradation of MDM2. It can reverse MDM2-targeted degradation of p53 w 0.05 mg
31-051 MDM4 inhibits p53- and p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. inhibits degradation of MDM2. It can reverse MDM2-targeted degradation of p53 whil 0.1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur